Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
Our high-tech, dedicated method is applied to construct targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.
Our library stands out due to several important features:
partner
Reaxense
upacc
Q5T442
UPID:
CXG2_HUMAN
Alternative names:
Connexin-46.6; Connexin-47; Gap junction alpha-12 protein
Alternative UPACC:
Q5T442; O43440; Q7Z7J2; Q8IWJ9
Background:
The Gap junction gamma-2 protein, also known as Connexin-47, plays a pivotal role in cell communication, facilitating the diffusion of materials between cells. This protein is integral to the formation of gap junctions, consisting of connexon channel pairs, crucial for myelination in the nervous systems.
Therapeutic significance:
Linked to diseases such as Leukodystrophy, hypomyelinating, 2, Spastic paraplegia 44, and Lymphatic malformation 3, the Gap junction gamma-2 protein's role in these conditions underscores its potential as a target for therapeutic intervention. Understanding its function could lead to breakthroughs in treating these debilitating diseases.